Who pays the ride home? Solving patient transportation in rural trials

A rural participant can meet every eligibility criterion, trust the study team, and still never enroll because there is no reliable way to get to the site and back home. Transportation is not a courtesy and not a recruitment gimmick. It is an access cost of research outside major metropolitan areas, and it belongs in the study budget, in writing, before the first participant is screened. When nobody owns that cost in advance, the site absorbs it quietly, the sponsor loses enrollments it already paid to generate, and the participant pays with a long drive home after a demanding visit.

The enrollment problem nobody budgets for

In urban trials, transportation is an inconvenience. In rural trials, it can be the deciding factor. Participants may live an hour or more from the site. Some no longer drive at night. Some depend on a spouse, an adult child, or a neighbor who must also miss work. Others cannot absorb fuel, tolls, parking, and a full day away from work or caregiving for every visit.

Those barriers compound. Screening is only the beginning. Follow-up visits, laboratory draws, imaging, device checks, and unscheduled safety visits all require another trip. A participant who manages the first visit may withdraw by the fourth, not because of the investigational product, but because the logistics became unsustainable. When transportation is the hidden reason eligible patients do not enroll, teams misread it as weak interest. It is an unfunded operational requirement, to be planned like staffing and investigator time.

Who actually pays: sponsor, site, or nobody

In most industry-sponsored trials, participant transportation should be a sponsor-funded study cost when it is necessary for access and retention. The cleanest approach is a defined line in the site budget, or a pass-through structure administered under the clinical trial agreement. The sponsor funds the conduct of the protocol. If the protocol requires repeated in-person visits from a dispersed population, the travel needed to complete those visits is part of the cost of generating complete and reliable data.

Sites sometimes absorb transportation informally at the start, booking a car here and reimbursing mileage there because a promising participant is about to be lost. That goodwill is not a system. It does not scale, it gives inconsistent support to participants in identical circumstances, and it distorts the true cost of the study.

Exceptions exist, such as grant-funded studies with strict allowable-cost rules. None of that changes the rule: decide who pays, how much, and through what process before enrollment opens. A cost discovered after activation becomes a dispute. The same cost presented during budgeting becomes a plan.

What sponsors expect to see before first enrollment

Sponsors do not need a sentimental appeal. They need a transport plan they can review, price, and defend internally. Include it in the recruitment plan and connect it directly to the budget request.

Start with geography and visit burden. Map where the target population lives, using referral patterns the site already holds. State typical distance and drive time, not just the best case. State how many in-person visits the protocol requires, which are longest, and where clustering or remote elements might reduce trips.

Next, define the structure and the oversight. Is support mileage reimbursement at a stated rate, a fixed amount per completed visit, a voucher, or a contracted ride? Who is eligible, based on distance, need, or both? How is a ride requested, approved, documented, and paid? Name the role that administers the plan, and describe how receipts and trip logs are retained and reported. The principal investigator (PI) remains responsible for study conduct at the site, so make clear that support never changes eligibility decisions, visit requirements, or safety reporting. It only removes a barrier to completing what the protocol requires.

Practical models that work in rural communities

No single model fits every study. The right choice depends on distance, mobility, visit frequency, local supply, and budget, and many sites combine two models.

Rideshare and voucher programs work where coverage is real, not theoretical. Confirm that drivers actually serve the participant's address, that vehicles can accommodate mobility needs, and that return trips can be scheduled after visits of uncertain length. A voucher that cannot be redeemed at a rural address is not a solution. Where coverage is thin, contracted local drivers are often more dependable: a vetted local provider or medical transport company can offer predictable pickup and flexibility when a visit runs long. Contract for response times, cancellation terms, insurance, driver screening, and confidentiality.

Mileage reimbursement is simple and respects independence for participants who drive themselves or have a trusted family driver. Keep the rate and payment timing transparent, and pay promptly. A reimbursement that arrives months later does not solve a fuel cost incurred today.

Visit clustering reduces the need itself. Where the protocol allows, combine laboratory work, assessments, and investigator review into one trip. Remote or decentralized elements can also help when the protocol and the institutional review board (IRB) permit them, such as telephone check-ins or local laboratory collection. Never redesign visit structure informally: changes affecting protocol procedures need sponsor approval and, where required, IRB approval before use.

Institutional review board and inducement: access is not coercion

Transportation support sometimes raises a cautious question: could paying for travel unduly influence a person to join or stay in a study? Handle it through disclosure and structure, not avoidance.

Support that reimburses real travel costs or provides a ride to required visits is access support. It offsets a burden created by participation. It becomes a concern when it is structured as a windfall, marketed as a reward, paid in a way that pressures a participant to ignore risk, or offered unevenly to steer specific people into enrollment. The safeguard is not to withhold support. It is to define it clearly, apply it consistently, and disclose it in the informed consent process as the IRB directs.

Put the terms in writing for IRB review: what is provided, who qualifies, any cost limits, and how support is described in recruitment materials. Never present assistance as earnings, a treatment benefit, or a reason to enroll. A participant must remain free to withdraw at any time, with nothing owed back. Documented, disclosed, and tied to actual visit completion, transportation support protects autonomy: it gives rural participants the same practical ability to consider research that urban participants already have by living closer to the site.

Track the real cost per enrolled participant

If transportation is not tracked, it cannot be managed, defended, or improved. Track it as an operational cost of recruitment and retention, not an afterthought.

Record cost by study and by visit: rides provided, mileage paid, vouchers redeemed, failed trips, and administrative time. Then calculate cost per screened participant, cost per enrolled participant, and cost per completed visit. Those three numbers tell very different stories. Add whether transportation was cited when a participant declined or withdrew.

That record changes future negotiations. A site can show that a defined investment protected enrollment, reduced missed visits, and lowered the cost of replacing lost participants. It also exposes waste: if one model produces repeated failed pickups, change it and document why. Review the numbers during the study, not only at closeout.

Start the conversation before the budget is final

The ride home should never be solved in a parking lot after a participant says they cannot return. Raise transportation during feasibility, price it in the budget, describe it in the recruitment plan, disclose it through the IRB process, and track it from the first trip. Sponsors gain better enrollment and retention. Sites gain a sustainable system instead of quiet absorption. Participants gain a fair chance to take part in research without subsidizing it themselves.

Rural participants are not harder to reach because they are less committed. They are harder to reach because distance is real. Fund the distance, and commitment can show itself.

About the author

Julio G. Martinez-Clark is CEO of Amavita Research Services, a Miami cardiovascular trial site with more than 18,000 active cardiology patients and zero Food and Drug Administration (FDA) Form 483 findings. He is also CEO of bioaccess, a first-in-human contract research organization (CRO) that runs early-stage trials anywhere from Canada down to Argentina.